These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 20664170)

  • 1. Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice.
    Hanson J; Gille A; Zwykiel S; Lukasova M; Clausen BE; Ahmed K; Tunaru S; Wirth A; Offermanns S
    J Clin Invest; 2010 Aug; 120(8):2910-9. PubMed ID: 20664170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of HCA₂ (GPR109A) in nicotinic acid and fumaric acid ester-induced effects on the skin.
    Hanson J; Gille A; Offermanns S
    Pharmacol Ther; 2012 Oct; 136(1):1-7. PubMed ID: 22743741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Seeing red: flushing out instigators of niacin-associated skin toxicity.
    Dunbar RL; Gelfand JM
    J Clin Invest; 2010 Aug; 120(8):2651-5. PubMed ID: 20664168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Langerhans cells release prostaglandin D2 in response to nicotinic acid.
    Maciejewski-Lenoir D; Richman JG; Hakak Y; Gaidarov I; Behan DP; Connolly DT
    J Invest Dermatol; 2006 Dec; 126(12):2637-46. PubMed ID: 17008871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing.
    Benyó Z; Gille A; Kero J; Csiky M; Suchánková MC; Nüsing RM; Moers A; Pfeffer K; Offermanns S
    J Clin Invest; 2005 Dec; 115(12):3634-40. PubMed ID: 16322797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nicotinic acid-induced flushing is mediated by activation of epidermal langerhans cells.
    Benyó Z; Gille A; Bennett CL; Clausen BE; Offermanns S
    Mol Pharmacol; 2006 Dec; 70(6):1844-9. PubMed ID: 17008386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. beta-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice.
    Walters RW; Shukla AK; Kovacs JJ; Violin JD; DeWire SM; Lam CM; Chen JR; Muehlbauer MJ; Whalen EJ; Lefkowitz RJ
    J Clin Invest; 2009 May; 119(5):1312-21. PubMed ID: 19349687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential tissue and ligand-dependent signaling of GPR109A receptor: implications for anti-atherosclerotic therapeutic potential.
    Gaidarov I; Chen X; Anthony T; Maciejewski-Lenoir D; Liaw C; Unett DJ
    Cell Signal; 2013 Oct; 25(10):2003-16. PubMed ID: 23770183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The niacin/butyrate receptor GPR109A suppresses mammary tumorigenesis by inhibiting cell survival.
    Elangovan S; Pathania R; Ramachandran S; Ananth S; Padia RN; Lan L; Singh N; Martin PM; Hawthorn L; Prasad PD; Ganapathy V; Thangaraju M
    Cancer Res; 2014 Feb; 74(4):1166-78. PubMed ID: 24371223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nicotinic acid.
    Pike NB
    J Clin Invest; 2005 Dec; 115(12):3400-3. PubMed ID: 16322787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Future of GPR109A agonists in the treatment of dyslipidaemia.
    Wanders D; Judd RL
    Diabetes Obes Metab; 2011 Aug; 13(8):685-91. PubMed ID: 21418500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-guided engineering of biased-agonism in the human niacin receptor via single amino acid substitution.
    Yadav MK; Sarma P; Maharana J; Ganguly M; Mishra S; Zaidi N; Dalal A; Singh V; Saha S; Mahajan G; Sharma S; Chami M; Banerjee R; Shukla AK
    Nat Commun; 2024 Mar; 15(1):1939. PubMed ID: 38431681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nicotinic acid (niacin) receptor agonists: will they be useful therapeutic agents?
    Kamanna VS; Kashyap ML
    Am J Cardiol; 2007 Dec; 100(11 A):S53-61. PubMed ID: 18047854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Niacin inhibits skin dendritic cell mobilization in a GPR109A independent manner but has no impact on monocyte trafficking in atherosclerosis.
    Ingersoll MA; Potteaux S; Alvarez D; Hutchison SB; van Rooijen N; Randolph GJ
    Immunobiology; 2012 May; 217(5):548-57. PubMed ID: 21798616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression.
    Lauring B; Taggart AK; Tata JR; Dunbar R; Caro L; Cheng K; Chin J; Colletti SL; Cote J; Khalilieh S; Liu J; Luo WL; Maclean AA; Peterson LB; Polis AB; Sirah W; Wu TJ; Liu X; Jin L; Wu K; Boatman PD; Semple G; Behan DP; Connolly DT; Lai E; Wagner JA; Wright SD; Cuffie C; Mitchel YB; Rader DJ; Paolini JF; Waters MG; Plump A
    Sci Transl Med; 2012 Aug; 4(148):148ra115. PubMed ID: 22914621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The psoriasis drug monomethylfumarate is a potent nicotinic acid receptor agonist.
    Tang H; Lu JY; Zheng X; Yang Y; Reagan JD
    Biochem Biophys Res Commun; 2008 Oct; 375(4):562-5. PubMed ID: 18722346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nicotinic acid receptor agonists differentially activate downstream effectors.
    Richman JG; Kanemitsu-Parks M; Gaidarov I; Cameron JS; Griffin P; Zheng H; Guerra NC; Cham L; Maciejewski-Lenoir D; Behan DP; Boatman D; Chen R; Skinner P; Ornelas P; Waters MG; Wright SD; Semple G; Connolly DT
    J Biol Chem; 2007 Jun; 282(25):18028-18036. PubMed ID: 17452318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High dietary niacin may increase prostaglandin formation but does not increase tumor formation in ApcMin/+ mice.
    Kwong AM; Tippin BL; Materi AM; Buslon VS; French SW; Lin HJ
    Nutr Cancer; 2011; 63(6):950-9. PubMed ID: 21774590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inflammation stimulates niacin receptor (GPR109A/HCA2) expression in adipose tissue and macrophages.
    Feingold KR; Moser A; Shigenaga JK; Grunfeld C
    J Lipid Res; 2014 Dec; 55(12):2501-8. PubMed ID: 25320346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of HDL metabolism by the niacin receptor GPR109A in mouse hepatocytes.
    Li X; Millar JS; Brownell N; Briand F; Rader DJ
    Biochem Pharmacol; 2010 Nov; 80(9):1450-7. PubMed ID: 20655299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.